First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial.

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

“…13 First-line high-dose chemotherapy plus rituximab followed by autologous stem-cell transplant has also not improved outcomes compared with rituximab-chemotherapy alone. 23,24 By contrast, in a study by the GELA group, 25 a signifi cant survival advantage was reported with R-ACVBP compared with R-CHOP-21 in 380 young patients with low-risk or low-intermediate-risk disease. After a median follow-up of 44 months, the 3-year eventfree survival was 81% in the R-ACVBP group compared with 67% with R-CHOP-21, and 3-year PFS was 87% and 73%, respectively.…”

Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity

“…(Table 1) Preliminary results of a randomized trial comparing R-CHOP-14 vs ASCT in young patients with DLBCL demonstrated no difference in outcome. 78 In a separate trial, conventional dose R-CHOEP-14 demonstrated a trend toward better outcomes compared with a high-dose therapy approach (R-Mega-CHOEP) for young high-risk patients with aggressive B-cell lymphoma. 79 An additional trial with a 2 3 2 factorial design evaluated rituximab dose-dense chemotherapy (R-CHOP-14 or R-Mega-CHOP-14) with or without the addition of ASCT in high-risk patients with DLBCL.…”

Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area

“…Lipocalin-2 from both myeloid cells and the epithelium combats Klebsiella pneumoniae lung infection in mice Elisabeth P. Cramer, 1 Sara L. Dahl, 1 Björn Rozell, 2 Kasper J. Knudsen, 3,4 Kim Thomsen, 5 Claus Moser, 5 Jack B. Cowland, 1,6 Lipocalin-2 is a eukaryotic siderophore-binding protein that prevents the growth and spread of microorganisms that require siderophoremediated uptake of soluble iron. 1 Consequently, lipocalin-2 knockout mice (Lcn2 2/2 mice) are more susceptible to infection with the siderophore-producing pathogen Klebsiella pneumoniae 2 than wildtype (WT) mice.…”

“…1 Consequently, lipocalin-2 knockout mice (Lcn2 2/2 mice) are more susceptible to infection with the siderophore-producing pathogen Klebsiella pneumoniae 2 than wildtype (WT) mice. Lipocalin-2 is a major constituent of neutrophilspecific granules 3 and can be induced in epithelial cells [4][5][6] and macrophages 7 during inflammation. In mice, lipocalin-2 is also produced in the liver as an acute phase protein.…”

“…To address this question, we analyzed all DLBCL patients treated in first line in 1 of the following prospective Lymphoma Study Association, Group of the Adult Lymphoma, and/or Acute Leukaemia and Blood Diseases West-East Group trials: LNH98-5, LNH-75, LNH03-2B, and LNH03-6B [3][4][5][6] (supplemental Figure 1, available on the Blood Web site). All patients received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or R-CHOP-like (mostly rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone [R-ACVBP]) regimens.…”